Core Viewpoint - The company emphasizes innovation as its core driving force and employs a dual-track strategy of "independent research and joint development" to advance its R&D efforts in innovative drug development, particularly focusing on areas such as anemia and the circulatory system [1] Group 1: R&D Strategy - The company is committed to enhancing its pipeline through various strategies, including technology introduction and changes in drug marketing authorization holders [1] - The core ongoing project involves expanding new indications for the drug Ruixiangsu capsules, with recent achievements including two invention patents for its applications in treating lymphatic reflux disorders and viral pneumonia, both currently in preclinical research [1] Group 2: Product Development - In addition to developing novel small molecule compounds, the company is also focused on improving existing products to enhance their clinical value and lifecycle [1] - The company plans to continuously increase investment in innovative drug R&D and expand its reserve of new technologies and products [1] Group 3: Communication and Reporting - The company will provide timely updates on its progress through regular reports and interim announcements [1]